http://www.zacks.com/stock/news/322513/mercks-keytruda-combo-gets-nod-for-lung-cancer-in-europe?cid=CS-ZC-FT-322513
Sep 11, 2018 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.
zc:6829824318399317499
0
http://www.zacks.com/stock/news/321571/mercks-keytruda-gets-priority-review-for-rare-skin-cancer?cid=CS-ZC-FT-321571
Sep 05, 2018 - Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.
zc:7517310741583482579
0
http://www.zacks.com/stock/news/317485/agenus-agen-q2-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-317485
Aug 10, 2018 - Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
zc:326003280341263274
0
https://www.fool.com/investing/2018/07/19/the-3-worst-healthcare-stocks-of-2018-so-far.aspx?source=iedfolrf0000001
Jul 19, 2018 - Find out how three companies have lost their shareholders a combined $31 billion so far this year.
0
fool:-8558326478019052708
0
http://www.zacks.com/stock/news/312300/cti-biopharma-tanks-post-type-b-talks-on-pacritinib-with-fda?cid=CS-ZC-FT-312300
Jul 19, 2018 - CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
zc:5699224010124426713
0
http://www.zacks.com/stock/news/312213/can-eli-lilly-lly-keep-the-earnings-streak-alive-in-q2?cid=CS-ZC-FT-312213
Jul 19, 2018 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
zc:-1975970960371967773
0
http://www.zacks.com/stock/news/310183/mercks-keytruda-gets-priority-review-in-difficult-lung-cancer?cid=CS-ZC-FT-310183
Jul 03, 2018 - Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.
zc:-7839573474905596525
0
https://www.fool.com/investing/2018/06/01/better-know-biotech-2-stocks-you-better-know-about.aspx?source=iedfolrf0000001
Jun 01, 2018 - These two small-cap biotech stocks could be about to make it big.
0
fool:-9016738975893200675
0
http://www.zacks.com/stock/news/305890/incyte-incy-up-102-since-earnings-report-can-it-continue?cid=CS-ZC-FT-305890
May 31, 2018 - Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
zc:-1757030286308709502
0
https://www.fool.com/investing/2018/05/31/3-biotechs-with-huge-fda-decisions-in-june.aspx?source=iedfolrf0000001
May 31, 2018 - The clock is ticking for these biotechs hoping to score key regulatory victories.
0
fool:5547016198331136781
0